Navigation Links
Signalife Achieves $1.98 Million Sales Orders Thus Far
Date:9/20/2007

LOS ANGELES, Sept. 20 /PRNewswire-FirstCall/ -- Signalife announced today that it has received orders for the sale of nearly $2,000,000 (two million dollars) of Fidelity 100 units thus far in its initial sales push being led by new management. Signalife, which anticipates additional sales orders resulting from its current efforts, shall announce such sales as and when they are completed.

About Signalife:

Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements:

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signa
'/>"/>

SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Inacom Information Systems achieves Cisco Systems Partner -Gold Certified status
2. Third Wave Achieves Milestone, Delivers 200,000 SNP Assays to RIKEN In Japan
3. Venture Investors early-stage fund grows to $115 million
4. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
5. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
6. TomoTherapy raises $223 million in IPO
7. Fiserv reports $113.5 million in Q1 profit
8. Investors raise $25 million for biodiesel plant
9. Grow Milwaukee includes millions for tech funding
10. Mirus Bio, Pfizer enter multimillion-dollar research agreement
11. ConjuGon raises $3.3 million to fund clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...France, April 23 , - Strong 10.3% Growth in F...the world leader in ophthalmic optics, today,annou...the three months ended,March 31, 2009, representin...f 2008. Excluding the currency effect, growth was ...and early in the year, revenue was down just 1%,li...
...l 22 Hovione held today the opening,ceremony of i...ing site in,Cork. Hovione contracted with Pfizer l...anufacturing Lipitor(R) since 1997. The handover o...ction closed on the 8th; going forward,Hovione wil...e for Pfizer but,will mostly make use of the avail...
...inducted into National Academy of Sciences for gro... WASHINGTON, April 22 Sir Philip Cohen of Scotlan...he U.S. National Academy of Sciences (NAS) during ...8:00 p.m. at the NAS building for his excellence i...of only four Scottish scientists ever inducted int...
Other Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
...ester scientists are to investigate the biological... after Alzheimer,s, thanks to a prestigious 1.9 mi...earch Council. , Frontotemporal lobar degeneratio...rontal and temporal lobes of the brain and are cha...rather than the memory loss associated with Alzhei...
...utions to Identify Individuals for Access to ...ions, WALL, N.J., Sept. 22 BIO-key International...er-based biometric,identification and wireless pub...etwork, is showcasing its fingerprint biometric so... being held at the Moscone Center in San,Francisco...
...A glitch in the ability to move iron around in cel...idosis (ML4) and the suite of symptoms---mental re...ies---that accompany it, new research at the Unive... may be involved in aging and neurodegenerative di...ead author Haoxing Xu, an assistant professor of m...
Other Biology News:£2 million study to reveal workings of dementia genes 2BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4Iron-moving malfunction may underlie neurodegenerative diseases, aging 2Iron-moving malfunction may underlie neurodegenerative diseases, aging 3
... containing a clone of the human Topoisomerase II ... topological state of nucleic acids by passing an ...enerates a separate DNA helix (1,2) . As a result ...enzyme can relax negatively or positively supercoi...
...I catalyzes the template-directed polymerization o...DNA Polymerase I possesses a 3?5 exonuclease activ...rror rate during DNA replication, and also contain...zyme to replace nucleotides in the growing strand ...
...e Klenow Fragment is a genetically engineered Klen...vity has been removed, leaving only the 5 to 3 pol...ctivity makes Exo- Klenow Fragment the enzyme of c...s by the random primed method, and for DNA sequenc...
T7 RNA Polymerase from Invitrogen
Biology Products: